Elanco Animal Health Incorporated (BMV:ELAN)
| Market Cap | 245.16B +25.3% |
| Revenue (ttm) | 92.79B +12.1% |
| Net Income | -2.65B |
| EPS | -5.65 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 20.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 533 |
| Open | 399.50 |
| Previous Close | 262.00 |
| Day's Range | 392.00 - 399.50 |
| 52-Week Range | 246.50 - 399.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
News
Elanco announces $600M share repurchase program
Elanco (ELAN) announced its board of directors has authorized the repurchase of up to $600M of the company’s common stock.
Elanco Announces Inaugural $600 Million Share Repurchase Authorization
Reflects Strengthening Financial Profile, Strong Cash Flow Generation, Successful Balance Sheet De-Leveraging Below 3x, and Confidence in Continued Momentum INDIANAPOLIS, Nov. 19, 2026 /PRNewswire/ --...
Elanco price target raised to $32 from $30 at Barclays
Barclays raised the firm’s price target on Elanco (ELAN) to $32 from $30 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3…
Elanco to Participate in Upcoming Investor Conferences
INDIANAPOLIS, Nov. 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Monday, November 30, Je...
Elanco Animal Health Transcript: UBS Global Healthcare Conference
Q3 organic growth was 9%, with 4% pricing and 300 bps of gross-margin expansion. The 2027 outlook remains mid-single-digit revenue growth, supported by innovation, volume and continued efficiency gains.
Elanco price target raised to $35 from $33 at JPMorgan
JPMorgan raised the firm’s price target on Elanco (ELAN) to $35 from $33 and keeps an Overweight rating on the shares.
Elanco Animal Health Earnings Call Transcript: Q3 2026
Q3 revenue rose 11% reported, with 300 bps of adjusted gross-margin expansion and 23% adjusted EBITDA growth. FY2026 guidance increased, while the 2027 growth algorithm was reaffirmed.
Elanco Animal Health Earnings release: Q3 2026
Elanco Animal Health released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Elanco Animal Health Slides: Q3 2026
Elanco Animal Health has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 6, 2026.
Elanco Animal Health Quarterly report: Q3 2026
Elanco Animal Health has published its Q3 2026 quarterly earnings report on November 6, 2026.
Elanco raises FY26 adjusted EPS view to $1.17-$1.20 from $1.10-$1.16
Consensus $1.13. Raises FY26 revenue view to $5.16B-$5.18B from $5.09B-$5.14B, consensus $5.13B. Raises FY26 adjusted EBITDA view to $1.05B-$1.07B from $1.01B-$1.04B. “Elanco (ELAN) achieved significa...
Elanco reports Q3 adjusted EPS 27c, consensus 20c
Reports Q3 revenue $1.27B, consensus $1.21B. “Third quarter results demonstrate Elanco (ELAN) is a consistent, reliable growth company, delivering our diverse portfolio of innovation along with accele...
Elanco Animal Health Reports Third Quarter 2026 Results
Accelerated Price, Organic Constant Currency Revenue Growth, and Gross Margin Expansion; Raising Full Year Outlook and Innovation Target; Achieved 2.9x Net Leverage Ratio Milestone Third Quarter 2026 ...
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Latest U.S. Survey of 2,000+ Consumers Shows 93% of Pet Owners Maintained or Increased Pet Spending in Past Three Months, Omnichannel Shift Redefines Purchasing INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/...
Elanco to Participate in UBS Global Healthcare Conference
INDIANAPOLIS, Nov. 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the UBS Global Healthcare Conference on November 9, 2026. Bob VanHimbergen, executive vice preside...
Elanco price target lowered to $25 from $26 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $25 from $26 and keeps an Equal Weight rating on the shares.
Elanco CPO Dave Kinard to retire, Jamie Preston to succeed
Elanco (ELAN) announced the appointment of Jamie Preston as executive VP and chief people officer, or CPO, effective November 3. Preston succeeds Dave Kinard, who intends to retire at the…
Elanco Animal Health Appoints Jamie Preston as Chief People Officer
Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard to retire at year-end INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Elanco Animal Health Inc...
Elanco downgraded to Hold from Buy at Jefferies
Jefferies downgraded Elanco (ELAN) to Hold from Buy with a price target of $24, down from $31. The firm cites the company’s softer pricing environment for the downgrade. The firm…
Elanco initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Elanco (ELAN) with a Buy rating and $32 price target The company has a diversified pharmaceuticals portfolio serving both pets and farm animals, the analyst…
What Growing Up on a Farm Taught Elanco's CEO
One of Jeff Simmons' pivotal leadership lessons came when he was 7 years old. Now CEO of Elanco Animal Health, Simmons said his family's upstate New York grape farm had been devastated by a hailstorm....
Elanco Animal Health Transcript: Bank of America Global Healthcare Conference
The event highlighted robust growth, innovation, and cash generation, with a strong pipeline of differentiated products and a focus on margin expansion. Strategic international rollout, operational efficiency, and targeted investments in vaccines and environmental solutions position the business for sustained mid- to high-single-digit growth and expanding profitability.
Elanco to Participate in BofA Securities Global Healthcare Conference 2026
INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
Elanco Animal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Pet health and farm animal markets are experiencing robust growth, driven by innovation, omni-channel expansion, and resilient demand. Differentiated products like Zenrelia, Quattro, and Befrena are gaining share, while margin improvements and a strong pipeline support long-term growth through 2027 and beyond.
Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low d...